Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Comparison of two score systems in Bcl-2 and Bax protein expression in invasive ductal carcinoma of breast and relation with oestrogen and progestrone receptors.

Ayatollahi H, Ghaffarzadegan K, Sharifi N, Farahmand MJ, Jarafian AH.

Breast J. 2009 May-Jun;15(3):310-2. doi: 10.1111/j.1524-4741.2009.00727.x. No abstract available. Erratum in: Breast J. 2010 Jan-Feb;16(1):113. Hossein, Ayatollahi [corrected to Ayatollahi, Hossein]; Kamran, Ghaffarzadegan [corrected to Ghaffarzadegan, Kamran]; Noorieh, Sharifi [corrected to Sharifi, Noorieh]; Javad, Farahmand Mohammad [corrected to Farahmand, Mohammad Javad]; Hossein, Jafarian Amir [corrected to Jarafian, Amir Hossein].

PMID:
19645793
2.

Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics.

Ringberg A, Anagnostaki L, Anderson H, Idvall I, Fernö M; South Sweden Breast Cancer Group.

Eur J Cancer. 2001 Aug;37(12):1514-22.

PMID:
11506959
3.

CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.

Pathol Res Pract. 2006;202(8):569-76. Epub 2006 Jul 7.

PMID:
16828238
4.

Microcysts and breast cancer: a study of biological markers in archival biopsy material.

Tran DD, Lawson JS.

Breast Cancer Res Treat. 2002 Oct;75(3):213-20.

PMID:
12353810
5.

Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.

Gonzalez LO, Corte MD, Junquera S, Bongera M, Rodriguez JC, Vizoso FJ.

Histopathology. 2007 Jun;50(7):866-74.

PMID:
17543076
6.
7.

The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.

de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J.

Histopathology. 2007 Aug;51(2):227-38.

PMID:
17650217
8.
10.

Expression of androgen receptors in primary breast cancer.

Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS.

Ann Oncol. 2010 Mar;21(3):488-92. doi: 10.1093/annonc/mdp510. Epub 2009 Nov 3.

11.
12.
13.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
15.
16.

The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.

Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R.

Cancer. 2004 Jun 1;100(11):2317-27.

17.

FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.

Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4415-21.

18.

Apoptosis in ductal carcinoma in situ of the breast.

Moreno A, Figueras A, Lloveras B, Escobedo A, Griera E, Sierra A, Fabra A.

Breast J. 2001 Jul-Aug;7(4):245-8.

PMID:
11678802
19.

Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.

Skalova A, Ryska A, Kajo K, Di Palma S, Kinkor Z, Michal M.

Histopathology. 2005 Jan;46(1):43-9. Review.

PMID:
15656885
20.

p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas.

Ioakim-Liossi A, Karakitsos P, Markopoulos C, Aroni K, Athanassiadou P, Delivelioti K, Athanassiades P, Vaiopoulos G.

Cytopathology. 2001 Jun;12(3):197-202.

PMID:
11380561
Items per page

Supplemental Content

Write to the Help Desk